Hertie-Institut Fuer Klinische Hirnforschung
Hertie-Institut Fuer Klinische Hirnforschung is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
Sponsor Universitaetsklinikum Tuebingen AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Hertie-Institut Fuer Klinische Hirnforschung?
The 2026-10-09 snapshot links Hertie-Institut Fuer Klinische Hirnforschung to 1 distinct CTIS trials. Recorded services include biobanking. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hertie-Institut Fuer Klinische Hirnforschung?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hertie-Institut Fuer Klinische Hirnforschung conducted?
The linked trials record locations in 6 countries, including Germany, Spain, France, Italy, Luxembourg. These are trial locations, not confirmed office locations or countries where Hertie-Institut Fuer Klinische Hirnforschung delivered services.
What can this page tell me about Hertie-Institut Fuer Klinische Hirnforschung's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hertie-Institut Fuer Klinische Hirnforschung. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hertie-Institut Fuer Klinische Hirnforschung